Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K. Yokoyama S, et al. Among authors: moriya t. J Viral Hepat. 2014 May;21(5):348-56. doi: 10.1111/jvh.12146. Epub 2013 Jul 30. J Viral Hepat. 2014. PMID: 24716637 Clinical Trial.
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. Takaki S, et al. Among authors: moriya t. Intervirology. 2007;50(6):439-46. doi: 10.1159/000114718. Epub 2008 Feb 4. Intervirology. 2007. PMID: 18253048 Clinical Trial.
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development.
Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group. Lange CM, et al. PLoS One. 2013 May 29;8(5):e64053. doi: 10.1371/journal.pone.0064053. Print 2013. PLoS One. 2013. PMID: 23734184 Free PMC article.
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group. Fujino H, et al. J Gastroenterol. 2014 Dec;49(12):1548-56. doi: 10.1007/s00535-013-0924-9. Epub 2013 Dec 21. J Gastroenterol. 2014. PMID: 24362944 Clinical Trial.
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Yokoyama S, Kawakami Y, Imamura M, Hayes CN, Kohno H, Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Takahashi S, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K. Yokoyama S, et al. Among authors: moriya t. J Gastroenterol Hepatol. 2015 Feb;30(2):337-44. doi: 10.1111/jgh.12706. J Gastroenterol Hepatol. 2015. PMID: 25091289
1,076 results